{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT00273884: Phase 2 Interventional Completed Acute Myeloid Leukemia
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Amonafide L-malate (AS1413, Xanafide) is a DNA intercalator and topoisomerase II inhibitor that induces apoptosis by disrupting chromatin organisation independently of ATP. This is different from classical topoisomerase II inhibitors which induce apoptosis by causing extensive DNA damage. Amonafide L-malate is also able to evade P-glycoprotein and related transporters that contribute to multi-drug resistance. AS1413 had orphan drug status in both the U.S. and the E.U. for the treatment of AML and also received Fast Track status from the U.S. FDA for the treatment of secondary AML. Amonafide L-malate was originated by Xanthus Pharmaceuticals. It was added to Antisoma's pipeline through the acquisition of Xanthus Pharmaceuticals, Inc. in June 2008. Antisoma discontinued development of Amonafide L-malate after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine missed the primary endpoint of significantly improving initial remission rate, defined as the proportion of patients who achieve CR or CRi, vs. daunorubicin plus cytarabine.
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nifuraldezone is an antibacterial compound. It completely mimics the radiosensitizing effect of molecular oxygen in hypoxic mammalian cells in vitro at concentrations in tissue culture medium which showed no measurable acute toxicity.
Class (Stereo):
CHEMICAL (ACHIRAL)
Alipamide is an antihypertensive and diuretic agent. It is a hydrazide derivative of m-sulfamoylbenzoic acid with diuretic activity. Alipamide primarily causes a saluretic effect and is able to inhibit carbonic anhydrase at higher doses which may also contribute to this agent's diuretic effect.
Class (Stereo):
CHEMICAL (ACHIRAL)
Amquinate is a quinolone coccidiostat. It is a powerful inhibitior of succinate and malate plus pyruvate supported respiration in E. tenella mitochondria. Amquinate is an antimalarial drug.
Status:
Investigational
Source:
NCT01393678: Phase 3 Interventional Completed Chronic Liver Disease
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
BIPHENYL DIMETHYL DICARBOXYLATE (BDD) under the brand name Nissel is used in the South Corea for the treatment of chronic hepatitis followed by an increase in serum alanine aminotransferase levels continuously. This compound also participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dinsed is a coccidiostat used in poultry to stop the growth of coccidian parasites.
Status:
Investigational
Source:
Int J Oral Maxillofac Surg. Feb 2016;45(2):186-93.: Not Applicable Human clinical trial Completed Sensation Disorders/etiology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Thiphencillin is a penicillin analog patented by Abbott Laboratories as an antibacterial agent. Thiphencillin shows potent antibacterial activity against various species and genera of pathogenic bacteria.
Status:
Investigational
Source:
Atherosclerosis. 1974;20(2):141-53.: Not Applicable Human clinical trial Completed Hyperlipidemias
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Nafenopin is a hypolipidemic drug. It is also a peroxisome proliferator. In rats and mice, nafenopin is a nongenotoxic hepatocarcinogen, which induces hepatic DNA synthesis and enzyme induction both in vivo and in hepatocyte cultures in vitro. Hepatic Ca2+ mobilization induced by nafenopin may play an important role in the mechanism by which nafenopin exerts its physiological as well as its tumour promotive activity upon chronic treatment with carcinogenic doses.
